Pharmacyclics LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- 607
- Market Cap
- -
- Website
- http://www.pharmacyclics.com
A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
Phase 1
Completed
- Conditions
- GliomaGlioblastomaAstrocytomaOligodendrogliomaBrain Neoplasm
- First Posted Date
- 2004-03-23
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 24
- Registration Number
- NCT00080054
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
Phase 1
Terminated
- Conditions
- Head and Neck CancerOropharynx CancerLarynx CancerHypopharynx Cancer
- First Posted Date
- 2004-03-23
- Last Posted Date
- 2007-05-08
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 18
- Registration Number
- NCT00080028
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸University of Texas, San Antonio Health Science Center, San Antonio, Texas, United States
A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Phase 2
Terminated
- Conditions
- LeukemiaLeukemia, Lymphocytic, Chronic
- First Posted Date
- 2004-01-26
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 27
- Registration Number
- NCT00076401
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
Phase 3
Completed
- Conditions
- Brain NeoplasmsCarcinoma, Non-Small-Cell LungMetastases, Neoplasm
- First Posted Date
- 2003-02-13
- Last Posted Date
- 2007-05-08
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 550
- Registration Number
- NCT00054795
© Copyright 2025. All Rights Reserved by MedPath